Prognostic alternative splicing signatures in esophageal carcinoma

Dlamini, Zodwa; Hull, Rodney; Mbatha, Sikhumbuzo Z.; Alaouna, Mohammed; Qiao, You-Lin; Yu, Herbert; Chatziioannou, Aristotelis

dc.contributor.author	Dlamini, Zodwa
dc.contributor.author	Hull, Rodney
dc.contributor.author	Mbatha, Sikhumbuzo Z.
dc.contributor.author	Alaouna, Mohammed
dc.contributor.author	Qiao, You-Lin
dc.contributor.author	Yu, Herbert
dc.contributor.author	Chatziioannou, Aristotelis
dc.date.accessioned	2021-09-10T13:17:28Z
dc.date.available	2021-09-10T13:17:28Z
dc.date.issued	2021
dc.description.abstract	Alternative splicing (AS) is a method of increasing the number of proteins that the genome is capable of coding for, by altering the pre-mRNA during its maturation. This process provides the ability of a broad range of proteins to arise from a single gene. AS events are known to occur in up to 94% of human genes. Cumulative data have shown that aberrant AS functionality is a major factor in human diseases. This review focuses on the contribution made by aberrant AS functionality in the development and progression of esophageal cancer. The changes in the pattern of expression of alternately spliced isoforms in esophageal cancer can be used as diagnostic or prognostic biomarkers. Additionally, these can be used as targets for the development of new treatments for esophageal cancer.	en_ZA
dc.description.department	Surgery	en_ZA
dc.description.librarian	pm2021	en_ZA
dc.description.uri	http://www.dovepress.com/cancer-management-and-research-journal	en_ZA
dc.identifier.citation	Dlamini, Z., Hull, R., Mbatha, S.Z., Alaouna, M., Qiao, Y.L., Yu, H., Chatziioannou, A. Prognostic Alternative Splicing Signatures in Esophageal Carcinoma. Cancer Management and Research 2021;13:4509-4527. https://doi.org/10.2147/CMAR.S305464.	en_ZA
dc.identifier.issn	1179-1322 (print)
dc.identifier.other	10.2147/CMAR.S305464
dc.identifier.uri	http://hdl.handle.net/2263/81754
dc.language.iso	en	en_ZA
dc.publisher	Dove Medical Press	en_ZA
dc.rights	© 2021 Dlamini et al. This work is published and licensed by Dove Medical Press Limited and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.	en_ZA
dc.subject	Esophageal squamous cell carcinoma	en_ZA
dc.subject	Adenocarcinoma	en_ZA
dc.subject	Splice variants	en_ZA
dc.subject	Cell surface receptors	en_ZA
dc.subject	Therapeutic targets	en_ZA
dc.subject	Biomarkers	en_ZA
dc.subject	Alternative splicing	en_ZA
dc.title	Prognostic alternative splicing signatures in esophageal carcinoma	en_ZA
dc.type	Article	en_ZA